You received anti-IL-23 antibody from a Pharmaceutical Company, requested your help in evaluating the efficacy of the antibody
1. You received anti-IL-23 antibody from a Pharmaceutical Company, requested your help in evaluating the efficacy of the antibody in patients with Atopic Dermatitis.
How do you plan the clinical studies?
How do you measure prognosis?
Prior to the clinical study, briefly summarize Atopic Dermatis: clinical symptoms, diagnosis etc.
2. You received IMATINIB from a Pharmaceutical Company, requested your help in evaluating the efficacy of the BCR-ABL Kinase inhibitor treatment in patients with Chronic Myeloid Leukemia (CML). How do you plan the clinical studies?
How do you measure prognosis?
Prior to the clinical study, briefly summarize CML: clinical symptoms, diagnosis, philadelphia chromosome, FISH TECHNIQUE etc.
a) learn more about the drug treatment you selected
d) how do you select your patients for treatment?
e) what questions do you ask
f) how do you set up the treatment plan?
g) how do collect the data?
h) how do you interpret the results
i) what conclusions do you make.
Answer preview for You received anti-IL-23 antibody from a Pharmaceutical Company, requested your help in evaluating the efficacy of the antibody
1338 Words